secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001370053-25-000023
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio reports positive rosnilimab RA data; Q4 net loss narrows to $21.8M; cash $420.8M
--------------------------------------------------------------------------------

- Rosnilimab achieved statistical significance on primary endpoint (DAS28-CRP) at Week 12 in Phase 2b RA trial; highest-ever CDAI LDA responses reported.
- Exclusive global license with Vanda for imsidolimab: $15M upfront, up to $35M milestones, 10% royalty on net sales.
- Cash and investments $420.8M at Dec 31, 2024; cash runway reiterated through year-end 2027.
- Collaboration revenue from GSK Jemperli milestones $43.1M in Q4 and $91.3M in FY2024; Jemperli 2024 sales $598M (>200% growth).
- Net loss $21.8M in Q4 ($0.72 loss per share) vs $42.2M in prior year; FY2024 net loss $145.2M ($5.12 per share).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005325000023/0001370053-25-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005325000023/anab-20250227.htm
  HTML page:      https://secwatch.observer/filing/0001370053-25-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer